Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + lenalidomide + dexamethasone re-induction followed by second ASCT in relapsed multiple myeloma
KCT0005635Phase 2Recruiting
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by Samyang Biopharmaceuticals Corporation. Started Nov 2021; status: recruiting.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0005635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005635.